1pm Plc Interim results 1H FY’19: geared up for growth

Hardman & Co

Hardman & Co Report Report Downloads1pm Plc (LON:OPM), We had been looking for two key themes with the 1H FY’19 results: i) that any early signs of credit deterioration were modest; and ii) that the integrations were going well. 1pm delivered on both. On credit, the net bad debt write-off was down on last year. Management detailed the diversification of the business, and commented how its operating flexibility, small individual exposures, human underwriting and fixed-rate lending should limit losses in a downturn. On group synergies, we note cross referrals are ticking up each month and the cost of group funds is falling. 1H FY’19 saw good franchise and revenue growth. The valuation appears anomalous with the group’s prospects.

1H FY’19 results: New business origination was up 10%, and revenue rose 15%. With cost of sales (including bad debts) increasing more slowly than revenue, gross profit was up 17%. Central control investment saw expenses rise 20%, and profit before tax was up 11%. Cost of funds continues to fall.

Outlook: These results were consistent with our FY’19 estimates, which are unchanged. Management outlined aggressive new targets for 2023, with a lending /invoice finance book of £350m (2018: £145m, 2014: £19m) and £90m+ of revenue (2018: £30m, 2014: £4m). It also outlined its strategy to achieve these targets, implying significantly more of the same, with selective acquisitions.

Valuation: We detailed the assumptions in our valuation approaches in our initiation note, Financing powerhouse: A lunchtime treat. The GGM indicates 116p and the DDM 69p (DDM normal pay-out 77p). The 2020E P/E (5.1x) and P/B (0.7x) appear an anomaly with 1pm’s profitability, growth and downside risk.

Risks: Credit risk is a key factor and is managed by each business unit according to its own specific characteristics, with a group overview of controls including the very recent appointment of a Group Head of Risk. Funding is widely diversified, and at least matches the duration of lending. Acquisitions would appear well priced, and delivery of synergies provides earnings upside.

Investment summary: 1pm offers strong earnings growth, in an attractive market, where management is tightly controlling risk. Targets to more than double the market capitalisation appear credible, with triggers to a re-rating being both fundamental (delivery of earnings growth, proof of cross-selling) and sentiment-driven (payback for management actively engaging the investor community). Profitable, growing companies generally trade well above NAV.

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search